Validation/NN
of/IN
Customized/JJ
Cancer/NN
Panel/NN
for/IN
Detecting/JJ
Somatic/JJ
Mutations/NNS
and/CC
Copy/NN
Number/NN
Alterations/NNS
./.
====================
Accurate/NN
detection/NN
of/IN
genomic/JJ
alterations/NNS
,/,
especially/RB
druggable/JJ
hotspot/NN
mutations/NNS
in/IN
tumors/NNS
,/,
has/VBZ
become/VBN
an/DT
essential/JJ
part/NN
of/IN
precision/NN
medicine/NN
./.
====================
With/IN
targeted/VBN
sequencing/NN
,/,
we/PRP
can/MD
obtain/VB
deeper/IN
coverage/NN
of/IN
reads/VBZ
and/CC
handle/NN
data/NNS
more/RBR
easily/RB
with/IN
a/DT
relatively/RB
lower/JJR
cost/IN
and/CC
less/RBR
time/NN
than/IN
whole-exome/DT
or/CC
whole-genome/JJ
sequencing/NN
./.
====================
Recently/RB
,/,
we/PRP
designed/VBD
a/DT
customized/JJ
gene/NN
panel/NN
for/IN
targeted/VBN
sequencing/NN
of/IN
major/JJ
solid/JJ
cancers/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
validate/VB
its/PRP$
performance/NN
./.
====================
The/DT
cancer/NN
panel/NN
targets/NNS
95/CD
cancer-related/VBD
genes/NNS
./.
====================
In/IN
terms/NNS
of/IN
the/DT
limit/VB
of/IN
detection/NN
,/,
more/RBR
than/IN
86/CD
%/NN
of/IN
target/NN
mutations/NNS
with/IN
a/DT
mutant/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
</JJR
1/CD
%/NN
can/MD
be/VB
identified/VBN
,/,
and/CC
any/DT
mutation/NN
with/IN
>/JJR
3/CD
%/NN
MAF/NN
can/MD
be/VB
detected/VBN
./.
====================
When/WRB
we/PRP
applied/VBD
this/DT
system/NN
for/IN
the/DT
analysis/NN
of/IN
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
DNA/NN
,/,
which/WDT
contains/VBZ
more/RBR
than/IN
500/CD
COSMIC/NN
mutations/NNS
across/IN
53/CD
genes/NNS
,/,
99/CD
%/NN
of/IN
the/DT
expected/VBN
mutations/NNS
were/VBD
robustly/RB
detected/VBN
./.
====================
We/PRP
also/RB
confirmed/VBD
the/DT
high/JJ
reproducibility/NN
of/IN
the/DT
detection/NN
of/IN
mutations/NNS
in/IN
multiple/JJ
independent/JJ
analyses/NNS
./.
====================
When/WRB
we/PRP
explored/VBD
copy/NN
number/NN
alterations/NNS
(/(
CNAs/NNS
)/)
,/,
the/DT
expected/VBN
CNAs/NNS
were/VBD
successfully/RB
detected/VBN
,/,
and/CC
this/DT
result/NN
was/VBD
confirmed/VBN
by/IN
target-specific/JJ
genomic/JJ
quantitative/JJ
polymerase/NN
chain/NN
reaction/NN
./.
====================
Taken/VBN
together/RB
,/,
these/DT
results/NNS
support/VBP
the/DT
reliability/NN
and/CC
accuracy/NN
of/IN
our/PRP$
cancer/NN
panel/NN
in/IN
detecting/VBG
mutations/NNS
./.
====================
This/DT
panel/NN
could/MD
be/VB
useful/JJ
for/IN
key/JJ
mutation/NN
profiling/VBG
research/NN
in/IN
solid/JJ
tumors/NNS
and/CC
clinical/JJ
translation/NN
./.
====================
Accurate/NN
detection/NN
of/IN
genomic/JJ
alterations/NNS
,/,
especially/RB
druggable/JJ
hot/JJ
spot/NN
mutations/NNS
in/IN
tumors/NNS
,/,
has/VBZ
become/VBN
an/DT
essential/JJ
part/NN
of/IN
precision/NN
medicine/NN
and/CC
medical/JJ
research/NN
./.
====================
Due/IN
to/TO
the/DT
advent/JJ
of/IN
next-generation/JJ
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
,/,
the/DT
ability/NN
to/TO
identify/VB
mutations/NNS
has/VBZ
increased/VBN
enormously/RB
,/,
which/WDT
has/VBZ
facilitated/VBN
the/DT
realization/NN
of/IN
precision/NN
medicine/NN
[/(
1/CD
]/)
./.
====================
However/RB
,/,
even/RB
with/IN
NGS/NN
technology/NN
,/,
the/DT
amount/NN
of/IN
whole-genome/JJ
sequencing/NN
(/(
WGS/NN
)/)
data/NNS
is/VBZ
too/RB
large/JJ
to/TO
handle/VB
by/IN
most/JJS
researchers/NNS
or/CC
clinicians/NNS
./.
====================
Whole-exome/DT
sequencing/NN
(/(
WES/NNS
)/)
,/,
which/WDT
targets/VBZ
the/DT
protein-coding/VBG
sequences/NNS
of/IN
whole/JJ
genomes/NNS
,/,
is/VBZ
more/RBR
efficient/JJ
and/CC
cost-effective/JJ
than/IN
WGS/NN
./.
====================
Therefore/RB
,/,
WES/NN
data/NNS
are/VBP
the/DT
most/JJS
commonly/RB
generated/VBN
NGS/NN
data/NNS
in/IN
the/DT
research/NN
field/NN
[/(
2/CD
]/)
./.
====================
However/RB
,/,
the/DT
amount/NN
of/IN
WES/NN
data/NNS
is/VBZ
too/RB
vast/JJ
for/IN
clinicians/NNS
to/TO
analyze/VB
and/CC
use/NN
in/IN
clinical/JJ
practice/NN
,/,
requiring/VBG
an/DT
expert/NN
./.
====================
In/IN
addition/NN
to/TO
data/NNS
size/VBP
issues/NNS
,/,
analyzing/VBG
WES/NN
data/NNS
needs/VBZ
experienced/VBN
bioinformaticians/NNS
,/,
which/WDT
is/VBZ
another/DT
big/NN
hurdle/JJ
for/IN
clinical/JJ
translation/NN
and/CC
application/NN
to/TO
basic/JJ
research/NN
./.
====================
The/DT
limited/JJ
amount/NN
of/IN
available/JJ
druggable/JJ
targets/NNS
is/VBZ
another/DT
practical/JJ
limitation/NN
of/IN
WES/NN
for/IN
clinical/JJ
translation/NN
./.
====================
Compared/VBN
with/IN
WES/NN
and/CC
WGS/NN
,/,
targeted/VBN
sequencing/NN
uses/VBZ
target/NN
enrichment/JJ
methods/NNS
to/TO
capture/NN
or/CC
amplify/VB
regions/NNS
of/IN
interest/NN
./.
====================
With/IN
targeted/VBN
sequencing/NN
,/,
we/PRP
can/MD
get/VB
deeper/IN
coverage/NN
of/IN
reads/VBZ
and/CC
handle/NN
data/NNS
more/RBR
easily/RB
with/IN
relatively/RB
lower/JJR
cost/IN
and/CC
less/RBR
time/NN
./.
====================
For/IN
these/DT
reasons/NNS
,/,
targeted/VBN
sequencing/NN
is/VBZ
noted/VBN
to/TO
identify/VB
hotspot/NN
mutations/NNS
and/CC
copy/NN
number/NN
alterations/NNS
(/(
CNAs/NNS
)/)
in/IN
cancer-related/JJ
genes/NNS
in/IN
the/DT
clinical/JJ
field/NN
and/CC
research/NN
./.
====================
It/PRP
enables/VBZ
one/CD
to/TO
diagnose/VB
quickly/RB
and/CC
accurately/RB
and/CC
suggest/VBP
appropriate/JJ
therapeutic/JJ
approaches/NNS
that/WDT
can/MD
elicit/VB
a/DT
favorable/JJ
treatment/NN
outcome/NN
[/(
3–5/CD
]/)
./.
====================
The/DT
flexibility/NN
of/IN
designing/VBG
the/DT
number/NN
of/IN
genes/NNS
and/CC
areas/NNS
of/IN
interest/NN
is/VBZ
another/DT
advantage/NN
of/IN
a/DT
customized/JJ
panel/NN
./.
====================
In/IN
the/DT
new/JJ
era/NNS
of/IN
precision/NN
medicine/NN
,/,
a/DT
number/NN
of/IN
institutes/NNS
have/VBP
developed/VBN
customized/VBN
target/NN
sequencing/NN
tools/NNS
for/IN
discovering/VBG
effective/JJ
therapeutic/JJ
agents/NNS
[/(
6–8/CD
]/)
./.
====================
In/IN
spite/NN
of/IN
these/DT
advantages/NNS
,/,
the/DT
performance/NN
of/IN
customized/VBN
panels/NNS
must/MD
be/VB
validated/VBN
,/,
such/JJ
as/IN
evenness/RB
of/IN
on-target/JJ
rates/NNS
and/CC
their/PRP$
sensitivity/specificity/NN
in/IN
detecting/VBG
mutations/NNS
[/(
9/CD
]/)
./.
====================
We/PRP
recently/RB
developed/VBD
a/DT
customized/JJ
NGS/NN
panel/NN
,/,
named/VBN
OncoChase-AS/NN
,/,
for/IN
targeted/VBN
sequencing/NN
of/IN
major/JJ
solid/JJ
cancers/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
validate/VB
its/PRP$
performance/NN
./.
====================
Samples/NNS
====================
To/TO
validate/VB
the/DT
performance/NN
of/IN
OncoChase-AS/NN
,/,
we/PRP
first/RB
tested/VBN
the/DT
limit/VB
of/IN
mutation/NN
detection/NN
by/IN
using/VBG
the/DT
Quantitative/JJ
Multiplex/JJ
Reference/NN
Standard/JJ
,/,
which/WDT
contains/VBZ
11/CD
mutations/NNS
across/IN
six/CD
cancer-related/JJ
genes/NNS
(/(
Horizon/NN
Discovery/NN
,/,
Cambridge/NN
,/,
UK/NN
)/)
./.
====================
Mutation/NN
detection/NN
was/VBD
examined/VBN
using/VBG
the/DT
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
,/,
a/DT
mixture/NN
of/IN
more/RBR
than/IN
500/CD
Catalogue/NN
of/IN
Somatic/JJ
Mutations/NNS
in/IN
Cancer/NN
(/(
COSMIC/NN
)/)
mutations/NNS
across/IN
53/CD
genes/NNS
./.
====================
Four/CD
cell/NN
lines/NNS
(/(
HCT116/NN
,/,
H1975/NN
,/,
SW620/CD
,/,
and/CC
HT29/NN
)/)
were/VBD
obtained/VBN
from/IN
the/DT
Korean/JJ
Cell/NN
Line/JJ
Bank/NN
and/CC
used/VBN
to/TO
assess/VB
the/DT
correlation/NN
with/IN
repeatability/NN
and/CC
reproducibility/NN
./.
====================
To/TO
test/VB
the/DT
identification/NN
of/IN
CNAs/NNS
,/,
we/PRP
used/VBD
two/CD
primary/JJ
tumors/NNS
that/WDT
are/VBP
known/VBN
to/TO
have/VB
CNAs/NNS
,/,
with/IN
the/DT
approval/JJ
of/IN
the/DT
institutional/JJ
review/NN
board/IN
of/IN
Catholic/JJ
University/NN
of/IN
Korea/NN
./.
====================
Genomic/JJ
DNA/NN
was/VBD
extracted/VBN
from/IN
these/DT
samples/NNS
using/VBG
the/DT
DNeasy/NN
Blood/NN
&/CC
Tissue/NN
Kit/NN
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
NGS/NN
and/CC
data/NNS
analysis/NN
====================
We/PRP
performed/VBD
NGS/NN
analysis/NN
for/IN
the/DT
DNA/NN
samples/NNS
with/IN
the/DT
OncoChase-AS/NN
cancer/NN
panel/NN
using/VBG
an/DT
Ion/NN
S5/NN
sequencer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
./.
====================
Raw/NN
sequence/NN
data/NNS
were/VBD
analyzed/VBN
with/IN
the/DT
Torrent/JJ
Suite/NN
(/(
Thermo/NN
Fisher/NN
Scientific/JJ
)/)
./.
====================
The/DT
aligner/NN
for/IN
mapping/VBG
reads/VBZ
to/TO
the/DT
reference/NN
genome/NN
is/VBZ
included/VBN
in/IN
the/DT
Torrent/JJ
Suite/NN
[/(
10/CD
]/)
./.
====================
To/TO
call/JJ
variants/NNS
from/IN
the/DT
mapped/VBN
sequence/NN
data/NNS
,/,
we/PRP
used/VBD
a/DT
plug-in/JJ
in/IN
the/DT
Torrent/JJ
Suite/NN
,/,
Torrent/JJ
Variant/JJ
Caller/NN
(/(
v5.2.2.41/NN
)/)
./.
====================
In/IN
order/NN
to/TO
annotate/VB
the/DT
called/VBN
variants/NNS
with/IN
the/DT
queried/VBN
knowledge/NN
database/NN
,/,
we/PRP
used/VBD
ANNOVAR/NN
[/(
11/CD
]/)
./.
====================
In/IN
order/NN
to/TO
verify/VB
variants/NNS
that/IN
were/VBD
not/RB
detected/VBN
by/IN
the/DT
Torrent/JJ
Variant/JJ
Caller/NNP
plug-in/JJ
,/,
we/PRP
confirmed/VBD
no-called/JJ
variants/NNS
using/VBG
the/DT
Integrative/JJ
Genomic/JJ
Viewer/NNP
(/(
IGV/NN
)/)
program/NN
[/(
12/CD
]/)
with/IN
binary/JJ
alignment/NN
mapping/VBG
(/(
BAM/NN
)/)
format/IN
files/NNS
as/IN
raw/RB
sequencing/NN
data/NNS
before/IN
calling/JJ
variants/NNS
[/(
13/CD
]/)
./.
====================
Limit/NN
of/IN
mutation/NN
detection/NN
====================
To/TO
verify/RB
the/DT
limit/VB
of/IN
detection/NN
,/,
we/PRP
used/VBD
the/DT
Quantitative/JJ
Multiplex/JJ
Reference/NN
Standard/JJ
DNA/NN
(/(
Horizon/NN
Discovery/NN
)/)
sample/JJ
,/,
which/WDT
contains/VBZ
11/CD
variants/NNS
with/IN
variant/JJ
allele/NN
frequencies/NNS
(/(
VAFs/NNS
)/)
ranging/VBG
from/IN
1/CD
%/NN
to/TO
24.5/CD
%/NN
./.
====================
We/PRP
diluted/VBD
the/DT
reference/NN
DNA/NN
from/IN
100/CD
%/NN
to/TO
10/CD
%/NN
and/CC
sequenced/VBN
it/PRP
with/IN
OncoChase-AS/NN
./.
====================
The/DT
limit/VB
of/IN
detection/NN
and/CC
correlation/NN
between/IN
the/DT
expected/VBN
and/CC
observed/VBN
VAFs/NNS
were/VBD
calculated/VBN
as/IN
described/VBN
[/(
14/CD
]/)
./.
====================
Correlation/NN
coefficient/JJ
and/CC
linear/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
using/VBG
R/NN
./.
====================
Concordance/NN
of/IN
variant/JJ
detection/NN
====================
To/TO
check/VB
the/DT
concordance/NN
of/IN
the/DT
detected/VBN
variants/NNS
,/,
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
DNA/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
was/VBD
used/VBN
./.
====================
NGS/NN
reactions/NNS
were/VBD
performed/VBN
with/IN
the/DT
OncoChase-AS/NN
panel/NN
in/IN
triplicated/JJ
runs/NNS
./.
====================
We/PRP
annotated/VBD
the/DT
variants/NNS
using/VBG
the/DT
ANNOVAR/NN
program/NN
[/(
11/CD
]/)
./.
====================
The/DT
criteria/NNS
for/IN
variant/JJ
calling/JJ
were/VBD
as/IN
follows/VBZ
:/:
exonic/JJ
variants/NNS
detected/VBN
in/IN
more/RBR
than/IN
5/CD
%/NN
in/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
and/CC
the/DT
Exome/NN
Aggregation/NN
Consortium/NN
(/(
ExAC/NN
)/)
Project/JJ
for/IN
East/JJ
Asian/JJ
and/CC
variants/NNS
with/IN
>/JJR
3/CD
%/NN
mutant/JJ
allele/NN
frequency/NN
(/(
MAF/NN
)/)
[/(
15/CD
,/,
16/CD
]/)
./.
====================
Reproducibility/NN
of/IN
mutation/NN
detection/NN
====================
To/TO
check/VB
the/DT
repeatability/NN
and/CC
reproducibility/NN
of/IN
the/DT
detection/NN
of/IN
mutations/NNS
,/,
especially/RB
mutations/NNS
with/IN
a/DT
low/JJ
VAF/NN
,/,
we/PRP
prepared/VBD
mixtures/NNS
of/IN
the/DT
DNAs/NNS
extracted/VBN
from/IN
four/CD
cell/NN
lines/NNS
(/(
H1975/NN
,/,
HCT116/NN
,/,
HT29/NN
,/,
and/CC
SW620/NN
)/)
./.
====================
NGS/NN
experiments/NNS
were/VBD
performed/VBN
in/IN
duplicate/JJ
by/IN
different/JJ
researchers/NNS
independently/RB
./.
====================
Detection/NN
of/IN
CNA/NN
====================
DNA/NN
copy/NN
number/NN
profiling/VBG
of/IN
the/DT
targeted/VBN
sequencing/NN
data/NNS
was/VBD
performed/VBN
using/VBG
NEXUS/NN
Copy/NN
Number/NN
,/,
v9.0/CD
(/(
BioDiscovery/NNP
,/,
El/NN
Segundo/NN
,/,
CA/NNP
)/)
./.
====================
CNA/NN
regions/NNS
were/VBD
defined/VBN
by/IN
a/DT
rank/NN
segmentation/NN
algorithm/NN
./.
====================
In/IN
the/DT
rank/NN
segmentation/NN
algorithm/NN
,/,
we/PRP
set/VBP
a/DT
threshold/JJ
for/IN
segmentation/NN
of/IN
p/NN
=/JJ
1.0E–6/CD
./.
====================
The/DT
thresholds/NNS
for/IN
copy/NN
number/NN
gain/NN
and/CC
loss/NN
were/VBD
0.3/CD
and/CC
−0.4/CD
on/IN
a/DT
log2/NN
scale/NN
,/,
respectively/RB
./.
====================
The/DT
thresholds/NNS
for/IN
amplification/NN
and/CC
homozygous/JJ
deletion/NN
were/VBD
1.0/CD
and/CC
−1.0/CD
on/IN
a/DT
log2/NN
scale/NN
,/,
respectively/RB
./.
====================
Design/IN
of/IN
the/DT
custom/JJ
cancer/NN
panel/NN
====================
The/DT
custom/JJ
NGS/NN
panel/NN
,/,
named/VBN
OncoChase-AS/NN
,/,
was/VBD
designed/VBN
to/TO
detect/VB
95/CD
cancer-related/VBD
genes/NNS
with/IN
clinically/RB
important/JJ
variants/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
95/CD
genes/NNS
were/VBD
selected/VBN
based/VBN
on/IN
the/DT
published/VBN
literature/NN
and/CC
cancer/NN
databases/NNS
,/,
such/JJ
as/IN
COSMIC/NN
[/(
17/CD
]/)
and/CC
GENIE/NN
[/(
18/CD
]/)
./.
====================
Of/IN
the/DT
95/CD
target/NN
genes/NNS
,/,
41/CD
genes/NNS
were/VBD
selected/VBN
for/IN
mutation/NN
screening/NN
,/,
10/CD
genes/NNS
were/VBD
selected/VBN
for/IN
CNA/NN
screening/NN
,/,
and/CC
the/DT
other/JJ
44/CD
genes/NNS
were/VBD
selected/VBN
for/IN
screening/VBG
of/IN
both/DT
mutations/NNS
and/CC
CNAs/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Limit/NN
of/IN
mutation/NN
detection/NN
====================
To/TO
determine/VB
the/DT
limit/JJ
of/IN
mutation/NN
detection/NN
with/IN
OncoChase-AS/JJ
,/,
we/PRP
used/VBD
the/DT
Quantitative/JJ
Multiplex/JJ
Reference/NN
Standard/JJ
DNA/NN
(/(
Horizon/NN
Discovery/RB
)/)
,/,
which/WDT
contains/VBZ
11/CD
mutations/NNS
with/IN
a/DT
1/CD
%/NN
to/TO
24.5/CD
%/NN
VAF/NN
across/IN
six/CD
cancer-related/JJ
genes/NNS
(/(
BRAF/NN
,/,
KIT/NN
,/,
EGFR/NN
,/,
KRAS/JJ
,/,
NRAS/NN
,/,
and/CC
PIK3CA/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
When/WRB
we/PRP
performed/VBD
NGS/NN
analysis/NN
with/IN
Onco-Chase-AS/NN
in/IN
duplicate/JJ
,/,
all/DT
of/IN
the/DT
expected/VBN
mutations/NNS
were/VBD
consistently/RB
identified/VBN
in/IN
both/DT
NGS/NN
analyses/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
To/TO
assess/VB
the/DT
limit/VB
of/IN
mutation/NN
detection/NN
,/,
we/PRP
serially/RB
diluted/VBN
the/DT
DNA/NN
sample/NN
from/IN
50/CD
%/NN
to/TO
10/CD
%/NN
and/CC
performed/VBN
NGS/NN
analysis/NN
with/IN
each/DT
diluted/VBN
DNA/NN
in/IN
duplicate/JJ
./.
====================
As/IN
a/DT
result/NN
,/,
mutations/NNS
with/IN
a/DT
very/RB
low/JJ
MAF/NN
(/(
</JJR
1/CD
%/NN
MAF/NN
)/)
were/VBD
successfully/RB
identified/VBN
in/IN
most/JJS
of/IN
the/DT
mutations/NNS
(/(
19/22/CD
,/,
86.4/CD
%/NN
)/)
./.
====================
Mutations/NNS
with/IN
a/DT
low/JJ
MAF/NN
(/(
1/CD
%/NN
to/TO
3/CD
%/NN
MAF/NN
)/)
were/VBD
also/RB
successfully/RB
identified/VBN
in/IN
most/JJS
of/IN
the/DT
mutations/NNS
(/(
23/26/CD
,/,
88.5/CD
%/NN
)/)
./.
====================
All/DT
mutations/NNS
with/IN
>/JJR
3/CD
%/NN
MAF/NN
were/VBD
detected/VBN
without/IN
exception/NN
(/(
40/40/CD
,/,
100/CD
%/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
more/RBR
than/IN
86/CD
%/NN
of/IN
the/DT
mutations/NNS
with/IN
</JJR
1/CD
%/NN
VAF/NN
can/MD
be/VB
identified/VBN
by/IN
NGS/NN
analysis/NN
with/IN
OncoChase-AS/NN
./.
====================
These/DT
results/NNS
also/RB
suggest/VBP
that/IN
any/DT
mutations/NNS
with/IN
>/JJR
3/CD
%/NN
frequency/NN
can/MD
be/VB
detected/VBN
with/IN
this/DT
platform/NN
./.
====================
When/WRB
we/PRP
calculated/VBD
the/DT
correlation/NN
between/IN
the/DT
expected/VBN
and/CC
observed/VBN
VAFs/NNS
by/IN
linear/JJ
regression/NN
analysis/NN
,/,
the/DT
R2/NN
value/NN
was/VBD
0.97/CD
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
This/DT
result/NN
further/RBR
supports/VBZ
the/DT
reliability/NN
of/IN
this/DT
system/NN
for/IN
variant/JJ
identification/NN
./.
====================
Performance/NN
in/IN
detecting/VBG
mutations/NNS
====================
To/TO
determine/VB
how/WRB
completely/RB
OncoChase-AS/RB
NGS/NN
detected/VBN
the/DT
expected/VBN
mutations/NNS
,/,
we/PRP
used/VBD
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
DNA/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
,/,
which/WDT
is/VBZ
a/DT
mixture/NN
of/IN
55/CD
tumors/NNS
that/DT
contain/VBP
more/RBR
than/IN
500/CD
COSMIC/NN
mutations/NNS
across/IN
53/CD
genes/NNS
./.
====================
Among/IN
the/DT
mutations/NNS
in/IN
the/DT
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
DNA/NN
,/,
OncoChase-AS/NN
targeted/VBN
358/CD
mutations/NNS
./.
====================
Therefore/RB
,/,
in/IN
principle/JJ
,/,
358/CD
mutations/NNS
are/VBP
expected/VBN
to/TO
detected/VBN
,/,
if/IN
OncoChase-AS/NN
NGS/NN
works/NNS
perfectly/RB
./.
====================
In/IN
the/DT
first/JJ
analysis/NN
,/,
353/CD
out/RP
of/IN
the/DT
358/CD
expected/VBN
mutations/NNS
were/VBD
detected/VBN
(/(
98.6/CD
%/NN
concordance/NN
)/)
./.
====================
In/IN
the/DT
second/JJ
analysis/NN
,/,
all/DT
358/CD
mutations/NNS
were/VBD
detected/VBN
(/(
100/CD
%/NN
concordance/NN
)/)
./.
====================
In/IN
the/DT
third/JJ
analysis/NN
,/,
the/DT
concordance/NN
rate/NN
was/VBD
98.6/CD
%/NN
(/(
353/358/CD
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
These/DT
results/NNS
indicate/VBP
that/IN
OncoChase-AS/NN
is/VBZ
fairly/RB
sensitive/JJ
and/CC
reliable/JJ
in/IN
identifying/VBG
mutations/NNS
./.
====================
Reproducibility/NN
of/IN
mutation/NN
detection/NN
====================
Cancer/NN
gene/NN
panels/NNS
can/MD
be/VB
used/VBN
for/IN
clinical/JJ
tests/NNS
,/,
such/JJ
as/IN
the/DT
identification/NN
of/IN
druggable/JJ
mutations/NNS
from/IN
tumor/NN
tissue/NN
or/CC
liquid/JJ
biopsy/NN
,/,
in/IN
addition/NN
to/TO
research/NN
./.
====================
Therefore/RB
,/,
the/DT
reproducibility/NN
of/IN
mutation/NN
detection/NN
is/VBZ
an/DT
important/JJ
issue/NN
./.
====================
To/TO
test/VB
the/DT
reproducibility/NN
of/IN
mutation/NN
detection/NN
,/,
we/PRP
performed/VBD
OncoChase-AS/RB
NGS/NN
with/IN
four/CD
cell/NN
lines/NNS
(/(
H1975/NN
,/,
HCT116/NN
,/,
HT29/NN
,/,
and/CC
SW620/NN
)/)
harboring/VBG
eight/CD
known/VBN
mutations/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
In/IN
this/DT
analysis/NN
,/,
cell/NN
line/NN
mixture/NN
samples/NNS
were/VBD
sequenced/VBN
in/IN
triplicate/NN
by/IN
two/CD
different/JJ
researchers/NNS
./.
====================
All/DT
of/IN
the/DT
expected/VBN
mutations/NNS
in/IN
mixtures/NNS
and/CC
the/DT
MAFs/NNS
were/VBD
measured/VBN
in/IN
every/DT
run/JJ
./.
====================
With/IN
these/DT
results/NNS
,/,
we/PRP
verified/VBD
the/DT
repeatability/NN
and/CC
reproducibility/NN
of/IN
the/DT
Onco-Chase-AS/NN
panel/NN
./.
====================
The/DT
average/JJ
repeatability/NN
and/CC
reproducibility/NN
were/VBD
98/CD
%/NN
(/(
ranging/VBG
from/IN
93/CD
%/NN
to/TO
100/CD
%/NN
)/)
and/CC
98/CD
%/NN
(/(
ranging/VBG
from/IN
95/CD
%/NN
to/TO
100/CD
%/NN
)/)
,/,
respectively/RB
(/(
Table/JJ
3/CD
)/)
./.
====================
Detection/NN
of/IN
CNAs/NNS
====================
Chromosomal/JJ
alteration/NN
is/VBZ
one/CD
of/IN
the/DT
most/JJS
commonly/RB
occurring/VBG
events/NNS
during/IN
tumorigenesis/NN
./.
====================
OncoChase-AS/RB
was/VBD
designed/VBN
to/TO
detect/VB
CNAs/NNS
for/IN
54/CD
genes/NNS
,/,
including/VBG
most/JJS
of/IN
the/DT
clinically/RB
important/JJ
CNAs/NNS
,/,
such/JJ
as/IN
ERBB2/NN
amplification/NN
and/CC
CDKN2A/B/NN
deletion/NN
./.
====================
To/TO
test/VB
whether/IN
OncoChase-AS/JJ
detected/VBN
CNAs/NNS
properly/RB
,/,
we/PRP
analyzed/VBD
two/CD
primary/JJ
tumors/NNS
(/(
brain/NN
cancer/NN
and/CC
sarcoma/NN
)/)
with/IN
known/VBN
CNAs/NNS
:/:
ERBB2/NN
amplification/NN
in/IN
a/DT
brain/NN
cancer/NN
and/CC
CDKN2A/NN
deletion/NN
in/IN
a/DT
sarcoma/NN
./.
====================
As/IN
a/DT
result/NN
,/,
the/DT
expected/VBN
CNAs/NNS
were/VBD
detected/VBN
precisely/RB
by/IN
OncoChase-AS/NN
NGS/NN
analysis/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
When/WRB
we/PRP
validated/VBD
the/DT
target/NN
CNAs/NNS
by/IN
genomic/JJ
quantitative/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
qPCR/NN
)/)
,/,
the/DT
results/NNS
were/VBD
consistent/JJ
with/IN
the/DT
NGS/NN
analysis/NN
results/VBZ
./.
====================
Although/IN
we/PRP
did/VBD
not/RB
test/VB
all/DT
54/CD
target/NN
genes/NNS
,/,
the/DT
current/JJ
results/NNS
indicate/VBP
that/IN
OncoChase-AS/NN
can/MD
robustly/RB
detect/VB
clinically/RB
important/JJ
CNAs/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
have/VBP
developed/VBN
a/DT
cancer/NN
panel/NN
containing/VBG
95/CD
cancer-related/VBD
genes/NNS
./.
====================
In/IN
terms/NNS
of/IN
the/DT
limit/VB
of/IN
detection/NN
,/,
OncoChase-AS/NN
can/MD
detect/VB
more/RBR
than/IN
86/CD
%/NN
of/IN
target/NN
mutations/NNS
with/IN
</JJR
1/CD
%/NN
MAF/NN
./.
====================
In/IN
the/DT
case/NN
of/IN
those/DT
with/IN
>/JJR
3/CD
%/NN
MAF/NN
,/,
any/DT
mutation/NN
can/MD
be/VB
detected/VBN
by/IN
NGS/NN
analysis/NN
with/IN
OncoChase-AS/NN
./.
====================
When/WRB
we/PRP
applied/VBD
this/DT
system/NN
for/IN
the/DT
analysis/NN
of/IN
Acrometrix/NN
Oncology/NN
Hotspot/NN
Control/NN
DNA/NN
,/,
which/WDT
contains/VBZ
more/RBR
than/IN
500/CD
COSMIC/NN
mutations/NNS
across/IN
53/CD
genes/NNS
,/,
99/CD
%/NN
of/IN
the/DT
expected/VBN
mutations/NNS
were/VBD
robustly/RB
detected/VBN
./.
====================
We/PRP
also/RB
confirmed/VBD
the/DT
very/RB
high/JJ
reproducibility/NN
of/IN
the/DT
mutation/NN
detection/NN
in/IN
multiple/JJ
independent/JJ
analyses/NNS
./.
====================
When/WRB
we/PRP
examined/VBD
CNAs/NNS
,/,
two/CD
expected/VBN
CNAs/NNS
related/JJ
to/TO
tumorigenesis/NN
were/VBD
successfully/RB
detected/VBN
,/,
and/CC
this/DT
result/NN
was/VBD
confirmed/VBN
by/IN
target-specific/JJ
genomic/JJ
qPCR/NN
./.
====================
All/DT
of/IN
these/DT
results/NNS
support/VBP
the/DT
reliability/NN
and/CC
accuracy/NN
of/IN
our/PRP$
Onco-Chase-AS/NN
platform/NN
in/IN
detecting/VBG
mutations/NNS
./.
====================
Therefore/RB
,/,
this/DT
panel/NN
could/MD
be/VB
helpful/JJ
for/IN
key/JJ
mutation/NN
profiling/VBG
research/NN
in/IN
solid/JJ
tumors/NNS
and/CC
clinical/JJ
translational/JJ
research/NN
,/,
because/IN
this/DT
panel/NN
covers/NNS
all/DT
14/CD
essential/JJ
genes/NNS
that/WDT
have/VBP
been/VBN
suggested/VBN
to/TO
be/VB
included/VBN
in/IN
cancer/NN
panels/NNS
for/IN
support/VBP
from/IN
the/DT
national/JJ
health/NN
insurance/RB
system/NN
in/IN
Korea/NN
./.
====================
There/EX
are/VBP
limitations/NNS
of/IN
our/PRP$
panel/NN
./.
====================
Due/IN
to/TO
the/DT
technical/JJ
limitations/NNS
of/IN
PCR/NN
amplification-based/VBN
NGS/NN
,/,
OncoChase-AS/NN
can/MD
not/RB
detect/VB
repeat/NN
sequences/NNS
with/IN
enough/JJ
reliability/NN
and/CC
reproducibility/NN
,/,
such/JJ
as/IN
microsatellite/NN
instabilities/NNS
and/CC
the/DT
promoter/NN
region/NN
of/IN
the/DT
TERT/NN
gene/NN
./.
====================
For/IN
this/DT
purpose/NN
,/,
a/DT
hybridization-based/JJ
targeted/VBN
sequencing/NN
panel/NN
would/MD
be/VB
more/RBR
suitable/JJ
./.
====================
The/DT
95/CD
target/NN
genes/NNS
in/IN
the/DT
OncoChase-AS/NN
panel/NN
./.
====================
CNA/NN
,/,
copy/NN
number/NN
alteration/NN
./.
====================
Correlation/NN
between/IN
expected/VBN
variant/JJ
allele/NN
frequency/NN
and/CC
observed/VBN
variant/JJ
allele/NN
frequency/NN
./.
====================
The/DT
correlation/NN
was/VBD
calculated/VBN
using/VBG
variants/NNS
that/WDT
were/VBD
detected/VBN
with/IN
>/JJR
3/CD
%/NN
allele/NN
frequency/NN
./.
====================
Copy/NN
number/NN
alterations/NNS
detected/VBN
by/IN
sequencing/NN
using/VBG
the/DT
Onco-Chase-AS01/NN
panel/NN
./.
====================
(/(
A/NN
)/)
ERBB2/NN
amplification/NN
in/IN
brain/NN
cancer/NN
patient/NN
and/CC
quantitative/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
result/NN
of/IN
ERBB2/NN
amplification/NN
./.
====================
(/(
B/NN
)/)
CDKN2A/NN
copy/NN
number/NN
deletion/NN
in/IN
sarcoma/NN
cancer/NN
patient/NN
and/CC
quantitative/JJ
PCR/NN
result/NN
of/IN
CDKN2A/NN
copy/NN
number/NN
deletion/NN
./.
====================
Limit/NN
of/IN
mutation/NN
detection/NN
====================
Concordance/NN
of/IN
mutation/NN
detection/NN
====================
Reproducibility/NN
and/CC
repeatability/NN
of/IN
mutation/NN
detection/NN
====================
